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Pulmonary fibrosis is a lung disease that is re-
fractory to treatment and carries a high mortal-
ity rate. It includes a heterogeneous group of 
lung disorders characterized by the progressive 
and irreversible destruction of lung architecture 
caused by scar formation that ultimately leads 
to organ malfunction, disruption of gas ex-
change,  and  death  from  respiratory  failure. 
Idiopathic pulmonary fibrosis (IPF), a particu-
larly severe form of pulmonary fibrosis with 
unknown etiology has a life expectancy of 2–6 yr 
after diagnosis (Selman et al., 2001). Lung fi-
brosis can also develop after viral infections and 
after exposure to radiotherapy, chemotherapeu-
tic drugs, and aerosolized environmental toxins 
(Denham and Hauer-Jensen, 2002; Kelly et al., 
2002;  Fubini  and  Hubbard,  2003;  Chen  and 
Stubbe, 2005). It also occurs in some bone mar-
row transplant recipients suffering from chronic 
graft versus host disease and in a subset of indi-
viduals with chronic inflammatory diseases like 
scleroderma and rheumatoid arthritis (Wolff  
et al., 2002; Young et al., 2007). Currently, the 
only effective treatment available for progres-
sive lung fibrosis is lung transplantation.
Repair of damaged tissues is a fundamental 
biological mechanism that allows the ordered 
replacement of dead or damaged cells after in-
jury, a process critically important for survival 
(Wynn, 2007). However, if this process becomes 
dysregulated, it can lead to the development of 
a permanent fibrotic “scar,” which is character-
ized by the excess accumulation of extracellular 
matrix (ECM) components (e.g., hyaluronic 
acid, fibronectin, proteoglycans, and interstitial 
collagens) at the site of tissue injury. Conse-
quently, fibrogenesis is often defined as an out 
of control wound healing response. Wound repair 
has four distinct stages that include a clotting/
coagulation phase, an inflammatory phase, a 
fibroblast migration/proliferation phase, and a 
final remodeling phase where normal tissue ar-
chitecture is restored (Fig. 1). In the earliest 
stages after tissue damage, epithelial cells and/or 
endothelial cells release inflammatory mediators 
that initiate an antifibrinolytic-coagulation cas-
cade that triggers clotting and development of 
a provisional ECM. Platelet aggregation and 
subsequent degranulation in turn promotes 
blood vessel dilation and increased permeabil-
ity, allowing efficient recruitment of inflam-
matory  cells  (e.g.,  neutrophils,  macrophages, 
lymphocytes, and eosinophils) to the site of 
injury. Neutrophils are the most abundant in-
flammatory cell at the earliest stages of wound 
healing, but are quickly replaced by macro-
phages after neutrophil degranulation. During 
this initial leukocyte migration phase, acti-
vated macrophages and neutrophils debride 
the wound and eliminate any invading organ-
isms. They also produce a variety of cytokines 
and chemokines that amplify the inflamma-
tory response and trigger fibroblast proliferation 
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Pulmonary fibrosis is a highly heterogeneous and lethal pathological process with limited 
therapeutic options. Although research on the pathogenesis of pulmonary fibrosis has 
frequently focused on the mechanisms that regulate the proliferation, activation, and 
differentiation of collagen-secreting myofibroblasts, recent studies have identified new 
pathogenic mechanisms that are critically involved in the initiation and progression of 
fibrosis in a variety of settings. A more detailed and integrated understanding of the  
cellular and molecular mechanisms of pulmonary fibrosis could help pave the way for 
effective therapeutics for this devastating and complex disease.
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in IPF (Demedts et al., 2005). An improved clinical, radio-
graphical,  and  histopathologic  classification  of  the  various 
forms and stages of pulmonary fibrosis and a more detailed 
understanding of the molecular mechanisms of fibrogenesis is 
needed so that therapies can be better tailored to specifically 
attack the underlying causes of the disease.
Although many forms of pulmonary fibrosis can be effec-
tively modeled and studied in rodents including drug (e.g., 
bleomycin), particulate-matter (e.g., asbestos and silica), radia-
tion, bronchiolitis obliterans, and chronic graft-versus-host–
induced pulmonary fibrosis, it remains unclear whether any 
of the experimental models truly duplicate the idiopathic 
form of the disease that is commonly seen in humans (Moore 
and  Hogaboam,  2008).  Nevertheless,  many  important  ad-
vances have been generated from rodent models, which have 
been dominated by transgenic and knockout mice that dis-
play either enhanced or decreased susceptibility to pulmonary 
fibrosis. These important studies have greatly expanded our 
understanding of the mechanisms of pulmonary fibrosis and 
are a major focus of this review.
Whereas nearly two decades of research have suggested 
that TGF- plays a central role in the pathogenesis of pulmo-
nary fibrosis by promoting the activation, proliferation, and 
differentiation of epithelial cells and collagen-producing 
myofibroblasts (Border and Noble, 1994), little progress has 
been made in moving TGF- pathway inhibitors from the 
bench to the bedside (Kisseleva and Brenner, 2008). In fact, 
there are still currently no approved drugs that specifically 
target any proposed mechanism of pulmonary fibrosis. Over 
the past few years several novel antifibrotic strategies have 
been described that do not involve targeting the TGF- sig-
naling pathway directly (Fig. 2). This review will highlight 
some of these exciting discoveries and illustrate how these 
and recruitment. Myofibroblasts are recruited from a variety 
of sources including local mesenchymal cells, bone marrow 
progenitors (called fibrocytes), and via a process called epithelial–
mesenchymal transition (EMT), wherein epithelial cells trans-
differentiate into fibroblast-like cells. The overall importance 
of each fibroblast population, however, remains unclear. 
Once  fibroblasts  become  activated,  they  transform  into   
-smooth muscle actin–expressing myofibroblasts that secrete 
ECM components. Finally, in the wound maturation/remod-
eling phase, myofibroblasts promote wound contraction, a pro-
cess where the edges of the wound migrate toward the center 
and epithelial/endothelial cells divide and migrate over the 
temporary matrix to regenerate the damaged tissue. Fibrosis 
develops when the wound is severe, the tissue-damaging irri-
tant persists, or when the repair process becomes dysregulated. 
Thus, many stages in the wound repair process can go awry 
and contribute to scar formation, likely explaining the com-
plex nature of pulmonary fibrosis.
Although the relative importance of inflammation in the 
progression of pulmonary fibrosis has been debated, many 
forms of the disease are believed to be induced, at least ini-
tially, by a strong inflammatory response (Crystal et al., 2002). 
Although some types of pulmonary fibrosis maintain a signif-
icant inflammatory component throughout the course of the 
disease, other forms like IPF are often characterized as exhib-
iting highly progressive fibrotic disease in the absence of de-
tectable inflammation (Thannickal et al., 2004). In this case, it 
has been hypothesized that intrinsic defects in the wound 
healing response involving lung epithelial cells and fibroblasts 
contribute  to  the  progression  of  fibrosis. The  fact  that  an   
active inflammatory response is not a strict prerequisite likely 
explains why standard antiinflammatory therapies, including 
corticosteroids and cytotoxic agents have shown little efficacy 
Figure 1.  Disruptions in normal wound healing contribute to the development of pulmonary fibrosis. Wound healing has four distinct stages: a 
clotting/coagulation phase (1), an inflammatory cell migration phase (2), a fibroblast migration/proliferation/activation phase (3), and a tissue remodeling 
and resolution phase (4). After lung injury, epithelial cells release inflammatory mediators that initiate an antifibrinolytic coagulation cascade, which trig-
gers platelet activation and blood clot formation. This is followed by entry of leukocytes (e.g., neutrophils, macrophages, and T cells). The recruited leuko-
cytes secrete profibrotic cytokines such as IL-1, TNF, IL-13, and TGF-. The activated macrophages and neutrophils also remove dead cells and eliminate 
any invading organisms. In the subsequent phase, fibrocytes from the bone marrow and resident fibroblasts proliferate and differentiate into myofibro-
blasts, which release ECM components. Fibroblasts and myofibroblasts may also be derived from epithelial cells undergoing EMT. In the final remodeling 
and resolution phase, activated myofibroblasts can promote wound repair, leading to wound contraction and restoration of blood vessels. However, fibro-
sis often develops if any stage in the tissue repair program is dysregulated or when the lung-damaging stimulus persists.JEM Vol. 208, No. 7  1341
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proinflammatory  cytokines  and  neutrophils  can  quickly 
evolve to a progressive fibrotic response (Kolb et al., 2001; 
Lappalainen et al., 2005). The IL-1 receptor antagonist damp-
ens the profibrotic effects of IL-1 (Ortiz et al., 2007), and 
studies with IL-1R1/, MyD88/, ASC/, Caspase-1/, 
and Nalp3/ mice have suggested that uric acid (induced 
by bleomycin), asbestos, and silica are detected by the Nalp3 
inflammasome in macrophages, leading to IL-1R1/MyD88 
signaling that is critical in the pathogenesis of particulate mat-
ter and bleomycin-driven fibrosis (Gasse et al., 2007, 2009; 
Cassel et al., 2008; Dostert et al., 2008).
IL-17A has also been implicated in the pathogenesis of 
pulmonary fibrosis (Langrish et al., 2005; Bettelli et al., 2006; 
Simonian et al., 2009; Wilson et al., 2010). IL-17A is increased 
in the bronchoalveolar lavage (BAL) fluid of patients with IPF 
(Wilson et al., 2010). IL-17A expression is associated with the 
persistent neutrophilia observed in a variety of lung disorders, 
including bacterial pneumonia and cystic fibrosis (Ye et al., 
2001; Decraene et al., 2010; Brodlie et al., 2011; Hsu et al., 
2011). Notably, recruitment of neutrophils to the BAL is an 
important predictor of early mortality in IPF patients (Kinder 
et al., 2008). IL-17A– and IL-17RA–dependent signaling are 
also important for the development of pulmonary fibrosis 
after exposure to bleomycin or Saccharopolyspora rectivirgula, a 
bacterium that causes hypersensitivity pneumonitis in rodent 
models (Simonian et al., 2009; Wilson et al., 2010). Detailed 
mechanistic studies in mice with bleomycin-induced fibrosis 
suggested that IL-23 and possibly IL-12 are important inducers 
of IL-17A–dependent fibrosis. Although  T cells are an 
important source of IL-17A, CD4+ T cells were identified 
as the dominant producer of IL-17A after bleomycin expo-
sure. Interestingly, IL-22 produced by  T cells protected 
mouse lungs from Bacillus subtilis–induced fibrosis, perhaps 
suggesting opposing roles for CD4+ Th17 cells and IL-22–
  expressing  T cells in the development of pulmonary fibro-
sis (Simonian et al., 
2010).  Bleomycin-
induced IL-17A pro-
duction is also highly   
unique targets and approaches might be exploited to treat this 
highly heterogeneous and complex disease. It also emphasizes 
that although many important advances have been made over 
the past few years, a great deal of work is needed before we 
can fully integrate all of the pathways and mechanisms that 
regulate the pathogenesis of pulmonary fibrosis.
A role for proinflammatory mediators in pulmonary fibrosis
It seems clear that inflammatory mediators play a role in both 
the initiation and progression of some forms of pulmonary 
fibrosis (Bringardner et al., 2008). Surgical biopsies and serum 
samples from patients with idiopathic or systemic sclerosis- 
associated pulmonary fibrosis display elevated levels of TNF 
and mice that overexpress the cytokine in the lung develop 
progressive pulmonary fibrosis (Piguet et al., 1993; Miyazaki 
et al., 1995; Hasegawa et al., 1997). Macrophages and many 
other cell types produce TNF in the lung after exposure to 
silica, asbestos, and bleomycin (Piguet et al., 1990; Piguet and 
Vesin, 1994; Zhang et al., 1993). Clinical trials were recently 
initiated to investigate if TNF pathway inhibitors like Etaner-
cept might be beneficial in the treatment of IPF (Raghu et al., 
2008). However, although inhibitors of TNF have shown effi-
cacy in some pulmonary fibrosis models, because TNF can 
inhibit collagen synthesis in myofibroblasts, TNF antagonists 
might have the undesired effect of worsening the disease (Siwik 
et al., 2000). Indeed, TNF blockade exacerbated pulmonary 
fibrosis in rheumatoid arthritis patients taking methotrexate 
(Thavarajah et al., 2009). Therefore, it remains unclear if  TNF 
blockade will ultimately prove beneficial in IPF or other forms 
of pulmonary fibrosis.
Like TNF, IL-1 can induce acute lung injury and may 
contribute to the progression of pulmonary fibrosis (Kolb et al., 
2001). Interestingly, IL-1–induced fibrosis is associated with 
increased  expression  of TNF,  suggesting  that  IL-1–  and 
TNF–triggered fibrosis might be linked mechanistically. The 
neutrophil attracting CXC chemokines CXCL1 (KC) and 
CXCL2 (MIP-2) are also increased by IL-1, as are the 
profibrotic cytokines platelet-derived growth factor (PDGF) 
and TGF-1, illustrating how acute lung injury initiated by 
Figure 2.  Proinflammatory and profi-
brotic mediators in the initiation and 
maintenance of fibrosis. Irritants like silica, 
asbestos, and bleomycin (uric acid) can injure 
lung epithelial cells and can be detected by 
the Nalp3 inflammasome in macrophages. 
These irritants stimulate the production of 
ROS, chemokines, and cytokines. These in-
flammatory mediators enhance the recruit-
ment and activation of leukocytes at the site 
of tissue injury. For example, IL-1 induces 
the activation of ROS-expressing neutrophils, 
which can further damage epithelial cells.  
IL-1 also promotes production of TGF-1, an 
important profibrotic cytokine that triggers 
fibroblast proliferation and activation. TGF- 
also targets epithelial cells, inducing EMT and 
the formation of ECM-producing myofibro-
blasts. TGF-1 further exacerbates the inflam-
matory response by stimulating the 
differentiation of Th17 cells. Interactive PPT 
slides for this figure are available online.1342 Mechanisms of pulmonary fibrosis | Wynn
activity, as prostaglandin F-2 , found in the BAL fluid of 
subjects with IPF, was shown to stimulate collagen produc-
tion  in  fibroblasts  through  a TGF-1–independent/PG(F) 
receptor–dependent mechanism (Oga et al., 2009). Never-
theless,  these  observations  illustrate  an  important  role   
for various mediators in inflammation-driven pulmonary   
fibrosis (Fig. 2).
Regulation by Th2 responses and IL-13
There is a great deal of evidence that CD4+ Th1 and Th2 cells 
play important roles during the inflammatory/maintenance 
phase of pulmonary fibrosis (Wynn, 2004). Indeed, cytokines 
associated with CD4+ Th1 and Th2 cells have exhibited con-
trasting activity in fibrogenesis (Wynn et al., 1995; Fig. 3). 
IFN- inhibits fibrosis, whereas the Th2-associated cytokines 
IL-4, IL-5, and IL-13 have been causally linked to the devel-
opment of fibrosis in a variety of chronic inflammatory 
diseases (Wynn, 2004). Transgenic mice that specifically over-
express IL-4 or IL-13 in the lung confirmed that both cyto-
kines function as profibrotic mediators by both directly and 
indirectly influencing the activation of myofibroblasts (Rankin 
et al., 1996; Zhu et al., 1999). IL-5 can also promote fibrosis 
in the lung by recruiting eosinophils that produce TGF-1, 
PDGF, and IL-13 (Huaux et al., 2003b; Cho et al., 2004; 
Fulkerson et al., 2006; Reiman et al., 2006). Nevertheless,   
detailed mechanistic studies conducted with IL-4 and IL-13 
inhibitors and il-4/, il13/, il-4ra/, and il13ra1/ mice 
suggest that the IL-13 signaling pathway likely serves as the 
dominant inducer of Th2-dependent fibrosis in several chronic 
lung diseases (Chiaramonte et al., 1999b; Kumar et al., 2002; 
Huaux et al., 2003a; Kolodsick et al., 2004; Yang et al., 2004; 
Lama et al., 2006; Keane et al., 2007; Ramalingam et al., 2008). 
IL-13 is detected in the BAL fluid of IPF patients, IPF fibroblasts 
are hyperresponsive to IL-13, and expression of both IL-13 
dependent on TGF-1 signaling, and recombinant IL-17A–
driven fibrosis is dependent on the downstream profibrotic 
activity of TGF-1, suggesting codependent roles for IL-17A 
and TGF-1 in the development of pulmonary fibrosis 
(Wilson et al., 2010).
Oxidative stress also perpetuates profibrotic inflammatory 
responses. Indeed, activation of the Nalp3 inflammasome and 
IL-1 secretion are largely driven by reactive oxygen species 
(ROS) derived by ROS-generating mitochondria (Naik and 
Dixit, 2011; Zhou et al., 2011) and NADPH oxidase (NOX) 
family members expressed in macrophages and neutrophils 
(Cassel et al., 2008; Dostert et al., 2008). NOX4 activity is 
induced in the lungs of mice after particle phagocytosis and 
promotes fibrogenesis in two distinct models of lung injury 
(Hecker et al., 2009). NOX4 is also increased in cases of human 
IPF. Mechanistically, NOX4 is required for TGF-1–induced 
myofibroblast differentiation, ECM synthesis, and fibro-
blast contractility.
In addition to directly promoting fibroblast activation, 
ROS, IL-1, and TNF can also promote fibrosis by increas-
ing expression of plasminogen activator inhibitor 1, which 
functions as a physiological inhibitor of the ECM degrad-
ing  plasmin/plasminogen  activator  system  that  protects 
mouse lungs from fibrosis (Liu, 2008). The plasmin/plas-
minogen  activation  system  also  increases  production  of 
prostaglandin E2 and COX-2, which exhibit potent anti-
fibrotic activity in the lung (Park and Christman, 2006;   
Bauman et al., 2010). The antifibrotic mediator prostaglan-
din E2 is also induced in the lungs of mice deficient in cyto-
solic  phospholipase A(2),  suggesting  that  antagonists  of 
cytosolic phospholipase A(2) might represent an additional 
strategy to treat fibrotic lung disease (Nagase et al., 2002; 
Peters-Golden et al., 2002; Wilborn et al., 1996). It is important 
to note, however, that not all prostaglandins exhibit antifibrotic 
Figure 3.  Specialized subsets of T helper 
cells and macrophages play distinct roles in 
pulmonary fibrosis. After injury, epithelial cells 
release IL-25, IL-33, and TSLP, which can facili-
tate the development of profibrotic Th2 re-
sponses. T cells also release IL-21 and IL-25, 
which promote Th2 differentiation. Th2 cells 
release IL-4 and IL-13, which promote the devel-
opment of a profibrotic macrophage subpopula-
tion that secretes TGF-1 among other 
mediators. IL-13 can also directly activate fibro-
blasts independently of TGF-1. Th2 cytokines 
also trigger specific chemokines that promote 
the recruitment of collagen-secreting fibrocytes 
from the bone marrow, which amplify fibrotic 
responses. The resulting myofibroblasts release 
ECM components. However, Th2 cytokines can 
also trigger antifibrotic feedback mechanisms. 
For example, Th2 cytokines activate arginase-1 
activity in M2 macrophages, which inhibit fur-
ther IL-13 production and myofibroblast differentiation. IL-13 can also up-regulate the IL-13 decoy receptor in fibroblasts, which antagonizes ECM production via 
a negative feedback loop. In addition, IFN-, produced by Th1 cells, exhibits potent antifibrotic activity by suppressing collagen synthesis in fibroblasts and by 
promoting the activation of inflammatory M1 macrophages that favor ECM degradation. Interactive PPT slides for this figure are available online.JEM Vol. 208, No. 7  1343
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by facilitating the recruitment of bone marrow–derived 
collagen–secreting  fibrocytes  to  the  lung  (Phillips  et  al., 
2004; Moore et al., 2005, 2006). Signals through the chemo-
kine receptors CCR2, CXCR3, and CXCR2 also regulate 
fibrosis associated with bronchiolitis obliterans syndrome, by 
regulating vascular remodeling and recruitment of mononu-
clear phagocytes and neutrophils (Belperio et al., 2001, 2002b, 
2005). The lysophosphatidic acid receptor 1 also controls the 
recruitment of fibroblasts in mice with bleomycin-induced 
fibrosis and levels of lysophosphatidic acid are increased in the 
BAL fluid of people with IPF (Tager et al., 2008).
Interestingly, however, not all chemoattractants promote 
pulmonary fibrosis. CXCL10, CXCL11, and CXCR3 inhibit 
bleomycin-induced fibrosis by preventing fibroblast recruit-
ment, decreasing angiogenesis in the lung, and by promoting 
the production of the antifibrotic cytokine IFN-, respec-
tively (Jiang et al., 2004, 2010; Burdick et al., 2005). Thus, dis-
rupting  and/or  augmenting  specific  chemokine  signaling 
pathways could have a significant impact on the progression 
of pulmonary fibrosis. Given the well-known redundancy in 
chemokine–chemokine receptor signaling, it will be impor-
tant to determine which forms and stages of pulmonary   
fibrosis might benefit from targeting these pathways.
Factors influencing epithelial cell and fibroblast 
differentiation and proliferation
Aberrant  activation  of  developmental  and  wound-healing 
pathways also contributes to the pathogenesis of pulmonary 
fibrosis, particularly in IPF, where ongoing inflammation is 
believed to play less of a role. For example, the Wnt–-catenin 
signaling pathway, which regulates homeostatic self-renewal 
in several adult tissues, is constitutively active in ATII cells in 
both a mouse model of pulmonary fibrosis and in patients 
diagnosed with IPF (Chilosi et al., 2003; Königshoff et al., 
2008, 2009). Treatment with WNT1-inducible signaling pro-
tein-1 (WISP-1) promotes proliferation and EMT of mouse 
ATII cells and synthesis of ECM components by mouse 
and  human  lung  fibroblasts.  Development  of  pulmonary   
fibrosis  in  bleomycin-treated  mice  is  reduced  when  the 
WNT1 pathway is blocked with WISP1-neutralizing anti-
bodies (Königshoff et al., 2009). Thus, as an inducer of EMT, 
WISP1 is a potential therapeutic target in IPF (Fig. 4; Thiery 
and Sleeman, 2006). The integrin 31, expressed on epithelial 
cells, is another important inducer of EMT. Therefore, the 
31 and Wnt–-catenin pathways both appear to be involved 
in the development of pulmonary fibrosis (Kim et al., 2009a).
Fibroblasts isolated from IPF patients also display consti-
tutive  changes  in  their  proliferative  ability  (Ramos  et  al., 
2001), fail to invade the ECM, and display altered expression 
of genes in matrix production and degradation (Lovgren   
et al., 2011), suggesting that intrinsic defects in the activation 
status of fibroblasts might contribute to the pathogenesis of 
pulmonary fibrosis. 1 integrin inhibits fibroblast prolifera-
tion when bound to polymerized type 1 collagen by facilitat-
ing the activation of the tumor suppressor phosphatase and 
tensin homologue (PTEN), which normally suppresses the 
and  IL-13R1  correlate  with  the  severity  of  the  disease 
(Murray et al., 2008; Park et al., 2009).
Consequently, recent studies have focused on elucidating 
mechanisms that regulate IL-13 effector function. In addition 
to expressing an IL-13 signaling receptor, a heterodimer com-
posed of the IL-4R and IL-13R1 subunits, fibroblasts also 
express a decoy receptor for IL-13, IL-13R2 (Chiaramonte 
et al., 2003). The latter exhibits four orders of magnitude 
increased affinity for IL-13 (Lupardus et al., 2010) and sup-
presses IL-13-IL-13R1–induced responses, including pul-
monary fibrosis (Wilson et al., 2007; Ramalingam et al., 2008; 
Zheng et al., 2008). IL-21 produced by T cells, IL-33, and 
thymic stromal lymphopoietin (TSLP) released from dam-
aged epithelial cells, as well as IL-25 produced by both   
T cells and epithelial cells, also represent potential targets for 
antifibrotic therapy, as each of these cytokines has been re-
ported to play a major role in the induction and/or amplifica-
tion of type 2 immunity (Fort et al., 2001; Schmitz et al., 
2005; Zhou et al., 2005; Pesce et al., 2006). Nevertheless, al-
though IL-21 regulates liver fibrosis during S. mansoni infec-
tion (Pesce et al., 2006) and IL-33 is a major inducer of 
IL-13–dependent  cutaneous  fibrosis  (Rankin  et  al.,  2010), 
few studies have examined whether these “Th2-initiating   
cytokines” participate in the development of pulmonary fi-
brosis (Ramalingam et al., 2009). In addition to focusing on 
upstream mediators that regulate IL-13 production, several 
groups have also been elucidating the downstream mecha-
nisms that are targeted by IL-13. IL-1 (Ingram et al., 2004), 
TGF-1 (Lee et al., 2001), adenosine (Blackburn et al., 2003), 
chitinase family members (Zhu et al., 2004; Lee et al., 2009), 
chemokines (Belperio et al., 2002a; Zhu et al., 2002; Ma et al., 
2004), matrix metalloproteinases (Lanone et al., 2002; Madala 
et al., 2010) and various fibroblast subsets (Chiaramonte et al., 
1999a; Murray et al., 2008; Shao et al., 2008) are emerging as 
important targets of profibrotic IL-13. Together, these studies 
support recent efforts investigating the therapeutic potential 
of IL-13 antagonists in IPF and other chronic lung diseases 
(Hariyawasam et al., 2009).
Chemokines recruit leukocytes and fibroblasts to the lung
Chemokines are a large family of chemoattractants that re-
cruit leukocytes, fibroblast precursors, and other key effector 
cells to sites of tissue injury and therefore represent potential 
targets for antifibrotic therapy (Strieter et al., 2007). Serum 
levels of CCL18 correlate negatively with declining pulmo-
nary function in patients with pulmonary fibrosis of various 
causes, suggesting that CCL18 might be developed as a serum 
biomarker of progressive pulmonary fibrosis (Prasse et al., 2006; 
Prasse et al., 2009).
Blocking or genetically deleting CCL2 (monocyte-chemo-
attractant protein-1), CCL6 (C10), or CCR1 provides signifi-
cant protection from bleomycin-induced pulmonary fibrosis, 
albeit through mechanisms that remain undefined (Smith 
et al., 1994; Moore et al., 2001; Tokuda et al., 2000; Belperio 
et al., 2002a). CXCL12, CCL12, and CCR2 also play important 
roles in FITC- and bleomycin-induced pulmonary fibrosis 1344 Mechanisms of pulmonary fibrosis | Wynn
development  of 
pulmonary fibro-
sis (Coward et al., 
2010).  Interestingly,  DNA  methyltransferase  inhibitors  re-
versed  epigenetic  modifications  and  protected  mice  from 
pulmonary fibrosis (Sanders et al., 2008). Therefore, because 
epigenetic modifications are potentially reversible, they may 
represent attractive targets for novel antifibrotic therapies.
Additional potential therapeutic targets and strategies
Peroxisome proliferator-activated receptors (PPARs) , /, 
and  are ligand-activated transcription factors that belong 
to the nuclear hormone receptor family and important regu-
lators of metabolic and inflammatory processes (Kostadinova   
et al., 2005). The receptors are found on a wide variety of 
tissues  in  the  lung,  including  airway  epithelial  cells  and 
smooth muscle cells, and PPAR signaling has been impli-
cated in the pathogenesis of a wide variety of inflammatory 
diseases of the lung (Huang et al., 2005). Agonists of the three 
receptors suppress inflammation by inhibiting the production 
of proinflammatory cytokines, including IL-1 and TNF, 
and by reducing the influx of neutrophils into the lung. Some 
PPAR ligands also reduce the expression of Th2 cytokines, 
adhesion molecules, and chemokines that function as major 
drivers of pulmonary fibrosis (Sime, 2008). PPAR agonists 
reduce the development of bleomycin-induced pulmonary 
fibrosis, and mice deficient in PPAR develop exacerbated 
lung fibrosis associated with increased production of IL-1 
and TNF (Genovese et al., 2005b). PPAR/ agonists also 
inhibit lung fibroblast proliferation and enhance the anti-
fibrotic properties of PPAR agonists. PPAR agonists display 
PI3K–Akt–S6K1 signaling pathway (Xia et al., 2008). IPF   
fibroblasts evade this inhibitory mechanism by displaying a 
pathological pattern of 1 integrin expression that leads to 
low PTEN activity and uncontrolled activation of the PI3K–
AKT–S6K1 pathway (Fig. 4). In support of this theory, mice 
deficient in PTEN display a prolonged fibroproliferative re-
sponse after tissue injury (Xia et al., 2008). Loss of either 
-arrestin1 or -arrestin2 was shown to block fibroblast inva-
sion into the ECM and to protect mice from bleomycin- 
induced fibrosis (Lovgren et al., 2011). In contrast, mice 
deficient in the cationic amino acid transporter Slc7a2 ex-
hibit  heightened  fibroproliferative  responses  and  increased   
Th2-cytokine–associated fibrosis (Thompson et al., 2008). 
Thus, intrinsic defects in fibroblast proliferative pathways   
can have a significant impact on the progression of pulmo-
nary fibrosis.
Epigenetic changes in fibroblasts have also been hypothe-
sized to contribute to the pathogenesis of fibrosis by prevent-
ing proliferating fibroblasts from returning to their resting 
state. A recent genome-wide methylation scan of fibroblasts 
revealed several DNA methylation modifications that were 
unique to collagen-secreting myofibroblasts obtained from fi-
brotic kidneys (Bechtel et al., 2010). One of these modifica-
tions led to the epigenetic silencing of Rasal1, a suppressor of 
the Ras protooncogene, which led to increased Ras activity 
and growth factor–independent proliferation of fibroblasts. 
This study was important because it provided a novel molec-
ular explanation for the sustained and heritable activation of 
fibroblasts that is often observed when fibrosis becomes   
advanced (Fig. 4). The targeted repression of known antifi-
brotic genes by hypermethylation may also contribute to the   
Figure 4.  Intrinsic changes in the activation 
status of epithelial cells and fibroblasts can 
promote growth factor–independent pulmo-
nary fibrosis. Wnt–-catenin signaling activated 
(for example) by WISP-1, is constitutively active 
in some ATII epithelial cells in IPF patients and in 
mice with bleomycin-induced pulmonary fibrosis. 
This signaling triggers EMT and synthesis of ECM 
components by fibroblasts. In healthy fibroblasts, 
collagen-mediated stimulation of 1 integrin 
(blue) up-regulates PTEN activity and inhibits 
proliferation. IPF fibroblasts, however, display a 
pathological pattern of 1 integrin expression 
and signaling that can lead to decreased PTEN 
expression, aberrant activation of PI3 kinase, and 
excessive proliferation. Profibrotic mediators also 
promote epigenetic changes in fibroblasts that 
contribute to the pathogenesis of fibrosis. For 
example, the promoter regions of various genes 
encoding autocrine growth and/or differentiation 
factors can be demethylated, leading to their 
sustained and heritable activation. In addition, 
tumor suppressor genes can become methylated 
(red flag) and therefore inactivated, leading to 
the sustained activation of oncogenes that pro-
mote growth factor–independent proliferation of 
fibroblasts. miRNAs (e.g., miR-21) may operate in 
a similar fashion by blocking the translation or 
promoting the degradation of tumor suppressor 
genes in fibroblasts.JEM Vol. 208, No. 7  1345
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(Iredale, 2007; Wynn and Barron, 2010). Studies conducted 
with CD11b-DTR mice showed that if macrophages were 
depleted during the early inflammatory/maintenance phase 
of a fibrotic response, scarring was reduced and myofibroblasts 
were decreased (Fig. 1). In contrast, if macrophages were de-
pleted  during  the  late  remodeling/recovery  phase,  fibrosis 
persisted (Duffield et al., 2005). This important study con-
firmed that macrophages could play distinct roles in the in-
flammatory and remodeling phases of wound healing and 
fibrosis. Macrophages inhibit fibrosis by secreting mediators 
that induce myofibroblast apoptosis, removing cellular debris 
that can drive inflammation, digesting and engulfing ECM 
components, and stimulating the production of collagen- 
degrading MMPs in a variety of cell types, including myo-
fibroblasts  and  neutrophils  (Atabai  et  al.,  2009; Wynn  and 
Barron, 2010). Th2 cytokine-stimulated macrophages that 
express the enzyme arginase-1 also exhibit potent antifibrotic 
activity (Pesce et al., 2009). An important goal of future re-
search  will  be  to  determine  if  the  pro-  and  antifibrotic   
activities of macrophages are performed by distinct subpopu-
lations or whether the same macrophage can adjust its pheno-
type over time in coordination with new stimuli found in the 
local environment. Harnessing the protective activity of anti-
fibrotic macrophages may be key to ameliorating established 
and progressive fibrosis, as restoration of normal tissue archi-
tecture can proceed only if the existing collagen matrix is 
successfully removed.
Conclusions and future perspectives
A variety of experimental models have been generated to 
study the mechanisms of pulmonary fibrosis (Moore and   
Hogaboam, 2008). However, the mouse bleomycin model 
has garnered the most attention, perhaps because it is a well- 
characterized and clinically relevant model of pulmonary 
fibrosis. Nevertheless, although it successfully models the 
early proinflammatory stages of the disease, because of the 
transient nature of the bleomycin response and the reversi-
bility of the fibrosis, it is unclear whether this model can 
truly replicate the chronic and progressive forms of the dis-
ease seen in humans. Epithelial damage, inflammation, EMT, 
myofibroblast activation, and repetitive cycles of tissue in-
jury are certainly important initiators of fibrosis. However, 
if we are to develop effective therapeutics for pulmonary fi-
brosis, a more detailed understanding of the complex envi-
ronmental, cellular, genetic, and epigenetic changes that 
synergize to promote the progression of chronic pulmonary 
fibrosis is needed. Inflammatory and profibrotic mediators 
likely serve as the trigger for the epigenetic modifications 
that are observed in epithelial cells, endothelial cells, and 
fibroblasts.  Therefore,  a  more  integrated  approach  that   
targets key inflammatory cytokines, profibrotic mediators, 
and  epigenetic  modifications  simultaneously  will  likely 
emerge as the most successful strategy to treat this highly 
complex and devastating disease. As there are numerous 
causes, forms, and stages of pulmonary fibrosis, the hetero-
geneous nature of the disease must be considered when 
similar protective activity and inhibit TGF-1–driven myo-
fibroblast differentiation in vitro and the profibrotic activity 
of TGF-1 in vivo (Burgess et al., 2005; Genovese et al., 
2005a; Milam et al., 2008). Thus, in cases where pulmonary 
fibrosis is associated with a persistent proinflammatory re-
sponse, PPAR ligands may prove beneficial.
MicroRNAs (miRNAs) are small, evolutionarily conserved, 
noncoding RNAs 22 nt in length that play important   
roles in a variety of pathophysiologic processes by blocking 
the translation or promoting the degradation of specific target 
mRNAs.  Unique  miRNA  expression  patterns  have  been 
identified in a variety of lung disorders including COPD, em-
physema, cystic fibrosis, asthma, lung cancer, and IPF, suggest-
ing that distinct subsets of genes are targeted by microRNAs 
in each disease (Nana-Sinkam et al., 2009). Recently, miR-21 
was identified in the lungs of patients with IPF and in mice 
with bleomycin-induced pulmonary fibrosis (Liu et al., 2010). 
In agreement with related studies (Thum et al., 2008; Kim   
et al., 2009b), miR-21 production was primarily localized to 
myofibroblasts and expression was tightly controlled by the 
profibrotic cytokine TGF-1 (Liu et al., 2010). Administra-
tion of miR-21 antisense probes decreased the severity of 
bleomycin-induced fibrosis in mice and attenuated the pro-
fibrotic activity of TGF-1 in fibroblasts, confirming a critical 
role for miR-21 in lung fibrogenesis. Interestingly, miR-21 
targets several tumor suppressor genes and promotes tumor 
growth and invasion (Fig. 4), suggesting it can function as an 
oncogene (Meng et al., 2007; Zhu et al., 2007, 2008; Asangani 
et al., 2008). miR-21 also operates as antiapoptotic factor in 
tumor cells (Chan et al., 2005). Thus, aberrant expression of 
miR-21  in  fibroblasts  could  promote  their  survival  and 
differentiation into pathogenic collagen-secreting myofibro-
blasts. Therefore, small-molecule inhibitors of miR-21 might 
be developed to treat IPF. Identifying specific miRNAs that 
block profibrotic genes or promote lung regeneration could 
also prove highly beneficial in the treatment of pulmonary   
fibrosis (Pandit et al., 2010).
Disease stage-specific roles of macrophages
Macrophages are integrated into all stages of the fibrotic pro-
cess, perhaps because they serve as key regulators of fibroblast 
recruitment, proliferation, and activation (Wynn and Barron, 
2010). They promote fibrosis by secreting chemokines and 
specific matrix metalloproteinases that degrade ECM com-
ponents,  thus  facilitating  the  recruitment  of  inflammatory 
cells to sites of tissue injury (Zuo et al., 2002; Jiang et al., 
2005). They also produce several profibrotic mediators, in-
cluding TGF-1 and PDGF that induce the proliferation and 
activation of collagen-secreting myofibroblasts (Song et al., 
2000). Alveolar  macrophages  isolated  from  fibrotic  lung 
tissues are also capable of producing profibrotic cytokines 
(Hancock et al., 1998; Ingram et al., 2004; Cassel et al., 2008; 
Wilson et al., 2010).
Nevertheless, although some macrophages clearly pro-
mote tissue fibrogenesis, other macrophage subpopulations 
may  facilitate  the  resolution  and/or  reversal  of  fibrosis   1346 Mechanisms of pulmonary fibrosis | Wynn
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